20001359-9

IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:	A1	(11) International Publication Number: WO 99/20608
C07D 217/22, 405/04, 401/06, 409/04, 491/04, A61K 31/47 // (C07D 491/04, 317:00, 221:00)		(43) International Publication Date: 29 April 1999 (29.04.99)

(21) International Application Number: PCT/EP98/06353

(22) International Filing Date: 5 October 1998 (05.10.98)

(30) Priority Data:
9721964.6 16 October 1997 (16.10.97) GB

(71) Applicant *(for GB only)*: PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(71) Applicant *(for all designated States except GB US)*: PFIZER INC. [US/US]; 235 East 42nd Street, New York, NJ 10017 (US).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: BARBER, Christopher, Gordon [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). FISH, Paul, Vincent [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(74) Agents: HAYLES, James, Richard et al.; Pfizer Limited, European Patent Dept., Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: ISOQUINOLINES AS UROKINASE INHIBITORS



(I)

(57) Abstract

Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein one of R^1 and R^2 is H and the other is $N=C(NH_2)_2$ or $NHC(=NH)NH_2$, and the other substituents are as defined herein, are urokinase (uPA) inhibitors.